Skip to main content

MediNatura™ News


MediNatura™ Announces the Return of Natural Pain Reliever Traumeel® to the U.S. Market. Pain relief without the risk of steroids, opioids, or NSAIDs

After being absent for the past two years, Traumeel® ointment and tablets are back on the U.S. market, courtesy of MediNatura™. Traumeel® is an unusually safe and effective German anti-inflammatory pain reliever backed by multiple clinical studies.

Berwyn, PA, February 15, 2017 – After being absent for the past two years, Traumeel® ointment and tablets are back on the U.S. market, courtesy of MediNatura™. Traumeel® is also available as an injection solution (Rx) for moderate-to-severe pain levels.

Over 100 million Americans suffer from chronic pain , and it is estimated that nearly 15,000 people die every year of overdoses involving prescription painkillers2 and 16,500 people die each year of NSAID-related problems3.

Why? Because when pain pills, such as ibuprofen and naproxen sodium fail to provide full relief, consumers take more pills than are recommended. With opioids, such as oxycodone, one can become addicted. And too-frequent steroid injections can result in joint degeneration and even ruptured tendons. Determining how to treat chronic pain can be a life-or-death decision. However, there is a truly safe and natural way to treat chronic pain.

A combination of 14 plant and mineral extracts, Traumeel® is an unusually safe and effective German anti-inflammatory pain reliever backed by multiple clinical studies4. It safely treats the pain from chronic conditions, including arthritis, sprains, traumatic injuries, inflammation, and degenerative conditions of the musculoskeletal system.

MediNatura™ imports Traumeel® ointment, tablets, and injections, as well as other injections, from Germany where they are manufactured in FDA-approved factories that manufacture according to strict European and U.S. pharmaceutical standards for purity and sterility.

Traumeel® ointment and tablets are available by prescription only. Talk to your doctor about using Traumeel® to reduce your chronic pain instead of facing the risks of steroids, opioids, and NSAIDs.

Full prescribing information is available here:

Full prescribing information for Traumeel® is available here: Traumeel® Ointment, Traumeel® Tablets, Traumeel® Injection


MediNatura’s Traumeel® and Zeel® Injections are Appropriate for Olympic and Professional Athletes

MediNatura™ Incorporated, a Delaware Corporation headquartered in greater Philadelphia, responded to queries from numerous medical practitioners by announcing that Traumeel® and Zeel® injections are free of performance enhancing drugs (PEDs) and are appropriate pain relief remedies for elite athletes.

Philadelphia, PA, August 6, 2016 – MediNatura™ Incorporated, a Delaware Corporation headquartered in greater Philadelphia, responded to queries from numerous medical practitioners by announcing that Traumeel® and Zeel® injections are free of performance enhancing drugs (PEDs) and are appropriate pain relief remedies for elite athletes.

MediNatura™ imports Traumeel® and Zeel® from Germany, where they are manufactured in FDA-audited factories according to strict US pharmaceutical standards for purity and sterility. Traumeel® and Zeel® injections are publically listed by the German National Anti-Doping Agency (NADA) as approved pain relieving remedies that can be injected on both an intra-muscular and an intra-articular basis (see http://www.nada.de). These medicines were also recently submitted to a prestigious US testing laboratory for the testing of banned substances and were found to be free of such substances. Furthermore, MediNatura™ is aware of scores of professional athletes in the US who are injected with Traumeel® and Zeel® to gain pain relief without the negative effects of steroids—Traumeel® and Zeel® have never caused any issues with the random drug screening tests conducted on professional athletes.

Traumeel® has been used successfully by the doctors who treat the German Olympic Team, German National Soccer Team, and professional soccer teams such as Real Madrid and Bayern Munich. Dr. Müller-Wohlfahrt, the team doctor for Bayern Munich, stated that “Doping with Traumeel® can be excluded with 100% certainty” (Product Monograph, 2013).

In a recent study designed under the supervision of Dr. Carlos Lozada (University of Miami) and Dr. Roland Moskowitz (University Hospitals Case Medical Center, Cleveland), Traumeel® and Zeel® were shown to deliver safe, statistically significant, and clinically relevant pain relief for moderate-to-severe osteoarthritis of the knee (Lozada, C., del Rio, E., Reitberg, DP., Smith, R., Kahn, C., & Moskowitz, RW. Ann Rheum Dis 2015 EULAR. Abstract 4268). Read Full Abstract Here

Full prescribing information: Traumeel®, Zeel®


Safe, Extra Relief Now Possible After Taking Maximum Dose of Pain Pills

Berwyn, PA, December 7, 2015 – According to a 2011 Centers for Disease Control and Prevention (CDC) report, it is estimated that nearly 15,000 people die every year of overdoses involving prescription painkillers1 and according to a 2003 report in WebMD, 16,500 people die each year of NSAID-related problems2. These tragedies typically occur when pain pills fail to provide full relief and consumers take more pills than are recommended. This occurs in three situations:

  • Their pain out-lasts the 10-day period for which continuous use of pain drugs are safe
  • They take the recommended dose of pills but still have pain -- recent European research shows that 54% of people do not get full relief
  • Stomach and liver damage are also possible when consumers abuse pain pills.
MediNatura™, the makers of T-Relief™ has begun a national advertising campaign encouraging consumers to not risk damage to their internal organs through over-medication. Rather, they could add natural T-Relief ointment to their appropriate pain regimens. T-Relief™ has no known interaction with other medicines and provides extra relief, safely.

Organic Upgrade
This campaign coincides with the launch of majorly improved T-Relief formulations. “We’ve added organic oils and extra medicine to make the best T-Relief yet!” said Cathy Raish, MediNatura’s head of product development. "New T-Relief ointment’s base formula has a wonderful feel because it now has organic aloe oil, organic coconut oil, organic safflower oil and natural shea butter. Plus we’ve added 10% more arnica than our previous formula which, combined with T-Relief’s 12 other natural pain relievers, provides deep safe relief.”

"We now offer an empty-tube guarantee, “said Jessly Raj, marketing director “Consumers can use the entire tube and get a full refund if they’re not satisfied.“

Availability
T-Relief™ is available in all health food stores like Wholefoods, Sprouts, and progressive chains like Wegmans and CVS. Click here to check a store near you.

We’re also excited to announce that T-Relief can now be purchased directly from MediNatura.com and T-Relief.com. This helps us develop a closer relationship with our consumers so we can understand and respond to their needs. Our sites offer special features, such as coupons and the ability to search for product details. Receive free shipping on purchases of $25 or more. Buy T-Relief Online!

About MediNatura Inc.
MediNatura™ Inc. is a pharmaceutical company with the mission of providing serious medicines with exceptionally low side effect profiles. It does this by making prescription and over-the-counter medicines from natural substances. MediNatura Inc. is headquartered in greater Philadelphia with a factory in Albuquerque New Mexico. Sources
  1. http://www.cdc.gov/vitalsigns/painkilleroverdoses/
  2. http://www.webmd.com/pain-management/news/20030130/when-relieving-pain-raises-risk
  3. Rheumatology 2015; DOI: 10.1093/rheumatology/keu332


Traumeel® Plus Zeel® an Emerging Alternative to Intra-Articular Steroids and Viscosupplement Injections for Pain Associated with Moderate to Severe Osteoarthritis of the Knee

MediNatura™ announced today that a recent double-blind, randomized, controlled trial presented at the European League against Rheumatism (EULAR) meeting in Rome, Italy demonstrated that its biological/mineral multi-extract combinations Traumeel® and Zeel® can be considered a safe and effective treatment for pain in moderate-to-severe knee OA. Effect sizes of pain relief were reported to be comparable to standard treatments such as viscosupplements and steroids, which make combined Traumeel® plus Zeel® injections a valuable option for many patient types.

Philadelphia, PA, June 16, 2015 – According to analysis of the first ever double-blind trial of Traumeel® and Zeel® on moderate to severe osteoarthritis of the knee, this treatment showed efficacy effect sizes that were consistent with those observed for the widely used intra-articular injections of hyaluronic acid (HA viscosupplementation), corticosteroids, and oral NSAIDs.3,4 Unlike oral NSAIDs, the safety profile of this treatment was benign with no signals of cardiovascular, gastrointestinal, or other concerning risks.3,4M The analysis, which highlights the efficacy and excellent safety profile of this treatment, was presented at the annual meeting of the European League against Rheumatism (EULAR) in Rome, Italy. The presentation was made by Dr. Carlos Lozada of the University of Miami, who along with Dr. Roland Moskowitz of University Hospitals Case Medical Center, Cleveland, contributed to the study design.

Osteoarthritis (OA), a progressive disorder characterized by structural damage to joints, affects more than 600 million people worldwide and over 10 million adults in the US. Musculoskeletal conditions, including OA, are the second leading cause of disability worldwide. Individuals who are the most severely affected by OA are seniors and women over age 55.1

The vast majority of people with OA of the knee have at least one other chronic health condition, which can complicate the pharmacological treatment of pain related to OA due to the potential of drug-to-drug interactions and an increased risk of adverse events.1 Therefore, treatment approaches must be evaluated according to not only their efficacy compared to standard treatments, such as injected corticosteroids and oral NSAIDs, but also based on their risk-benefit ratio.

“We believe that our products will become an important treatment for physicians caring for patients with osteoarthritis of the knee,” said Stefan Luft, PhD, National Director of Sales and Medical Education, MediNatura™. “The products’ unique approach and proven clinical efficacy offer an innovative treatment option to patients who are seeking clinically relevant but safe pain relief.”

“These compounds have been available and used intra-articularly for a long time,” according to lead study author Carlos Lozada, MD, a rheumatologist in the University of Miami Health System. Among clinicians who have administered the treatment, the impression “has been that there was something there, but there were no double-blind data to support that,” he said, which was the rationale for the trial. “The study was undertaken to see if there was a true effect.”

The study enrolled 232 patients at 30 sites in the United States and was first presented at the recent annual meeting of the American College of Rheumatology (ACR). Eligible patients were men and women ages 45 to 80 with moderate-to-severe chronic knee osteoarthritis, based on both clinical and radiographic criteria, who were taking either an NSAID or acetaminophen for pain.4,5

Patients were randomized 1:1 to either Tr14 (Traumeel) plus Ze14 (Zeel) or a matching placebo, injected intra-articularly on days 1, 8, and 15, the standard injection schedule in clinical treatment. Patients were evaluated every 2 weeks.

On the primary endpoint, which involved the change from baseline on the knee subscale of the WOMAC A (Pain) Scale, treatment with Tr14/Ze14 performed significantly better than placebo beginning at day 15 (at the time of the final injection) and continuing through at all study visits except for day 29. The treatment’s superiority to the placebo was also seen in the secondary endpoint of pain following a 50 meter unassisted walk.5

Adverse events were generally mild and unrelated to treatment, Lozada said, and there were no treatment-related serious adverse events.2,4

References

  1. http://oarsi.org/education/oarsi-resources/press-release-march-2014-updated-guidelines
  2. Lozada, C., del Rio, E., Reitberg, DP., Smith, R., Kahn, C., and Moskowitz, RW. Arth Rheumat 66 (10) Suppl.: S1266 (Abstr 2896)
  3. Bannuru et al. Ann Intern Med; 162: 1/6/15:p46-54
  4. Lozada, C., del Rio, E., Reitberg, DP., Smith, R., Kahn, C., and Moskowitz, RW. Ann Rheum Dis 2015 EULAR. Abstract 4268
  5. http://www.medscape.org/viewarticle/841173_5


MediNatura™ now offers Traumeel and Zeel injections for knee OA

Philadelphia, PA, April 7, 2015 – MediNatura™ Incorporated, a Delaware Corporation headquartered in greater Philadelphia, announced today that the company has become the exclusive importer for the following injection solutions: Traumeel®, Zeel®, LymphomyosotX®, Spascupreel®, Neuralgo-Rheum® and Engystol®.

MediNatura™ is particularly excited to offer Traumeel® and Zeel®, given the recent clinical study results presented at the 2014 American College of Rheumatology (ACR) Annual Meeting. The study results demonstrated that co-administered Traumeel® (Tr14) and Zeel® (Ze14) intra-articular (IA) injections are safe and effective treatments for moderate to severe pain associated with knee osteoarthritis (OA) versus IA placebo. Specifically, these results showed statistically and clinically relevant pain relief for knee OA. The results were presented at ACR by Carlos Lozada, M.D., who together with Roland Moskowitz, M.D., helped design the trial. The abstract is available here: www.acrabstracts.org/abstracts/a-multi-center-double-blind-randomized-controlled-trial-db-rct-to-evaluate-the-effectiveness-and-safety-of-co-administered-traumeel-tr14-and-zeel-ze14-intra%E2%80%91articular-ia/.

"This study provides clinical evidence to support knee OA treatment with Traumeel® and Zeel®, providing an additional treatment option especially important for those patients who cannot tolerate non-steroidal anti-inflammatory drugs (NSAIDs), are not candidates for corticosteroid treatment or do not respond to other therapies," noted study co-investigator Roland Moskowitz, M.D., Clinical Professor of Medicine, University Hospitals, Case Medical Center.


VIDEO: Homeopathic injectables topped placebo for knee osteoarthritis

By: M. ALEXANDER OTTO, Rheumatology News Digital Network

MAUI, HAWAII, February 20, 2015 – Two homeopathic injectables, as well as the familiar combination of glucosamine and chondroitin, showed promise in two studies of alternative treatments for osteoarthritis.

In an interview at the 2015 Rheumatology Winter Clinical Symposium, Dr. Martin J. Bergman, of the department of rheumatology at Drexel University in Philadelphia, shared the recent results from the two investigations.

The first pitted intra-articular injections of two homeopathic products, Traumeel and Zeel, against placebo saline injections for knee osteoarthritis; the work was sponsored by the products’ German maker, Biologische Heilmittel Heel.

In the second trial, glucosamine and chondroitin sulfate went head to head against celecoxib (Celebrex), also for knee OA. The work was sponsored by Bioibérica, a Spanish company that makes chondroitin and glucosamine, and the investigators reported financial ties to the company.

Traumeel and Zeel may sound exotic, but they aren’t unknown in the rheumatology world – some U.S. rheumatologists are using them, Dr. Bergman, also chief of rheumatology at Taylor Hospital in Ridley Park, Pa., said.

Dr. Bergman disclosed that he has served as an advisor, speaker, or consultant for AbbVie, Amgen, Celgene, and Roche, and holds shares in Bristol-Myers Squibb, Johnson & Johnson, and Pfizer.

Cick here to view the video.


MediNatura™ Incorporated Finalized Purchase of Heel Incorporated

Philadelphia, PA, September 11, 2014 – MediNatura™ Incorporated, a Delaware Corporation headquartered in greater Philadelphia, today announced that it has finalized the purchase of the Heel Group's USA operations for over-the-counter (OTC) medications.

MediNatura™ Incorporated, a Delaware Corporation headquartered in greater Philadelphia, today announced that it has finalized the purchase of the Heel Group's USA operations for over-the-counter (OTC) medications.

MediNatura's full product line will be introduced in late 2014, and is designed to treat the same indications as the former Heel line, also using natural homeopathic medicines. Heel Inc. products will be available via distributors through the end of this year.

"Most of MediNatura's products will be made in the same factory in New Mexico, following the same FDA-regulated practices, and by the same dedicated workers," said Scott Mitchell, vice president of operations for MediNatura and ex-director of operations for Heel Inc.

MediNatura will make available the following retail products: ClearLife™ (allergy), ReBoost™ (cold/flu), WellMind™ (calming, focus) and BodyAnew Cleanse™. Additionally, MediNatura's T-Relief™ (which relieves joint pain, back pain and muscular pain) and T-Relief Arthritis™ (for arthritis pain, joint pain and joint stiffness) will feature all-natural, active ingredients. The BHI line of products will remain unchanged.

Customers can contact 1.844.633.4628 with questions.


MediNatura™ Inc. Announces Agreement to Purchase Heel Inc.

Philadelphia, PA, May 30, 2014 – MediNatura™ Incorporated, a Delaware Corporation headquartered in greater Philadelphia, today announced an agreement to purchase the Heel Group's USA operations, which is expected to be completed in late August 2014. Completion of the stock transfer is subject to standard closing procedures.

Current Heel Inc. products will be available to USA distributors through August 2014, and to retailers and medical practitioners through December 2014.

"We remain committed to serving the needs of our practitioners, retailers and the many people that rely on these medicines, while providing outstanding customer service throughout this transition," said Jocelyn Levesque, MediNatura's vice president of sales, and director of sales for Heel Inc.

MediNatura's line of over-the-counter (OTC) products will be available to distributors and retailers beginning January 1, 2015. The following retail brands will be reformulated: ClearLife™ (allergy), Reboost™ (cold/flu), WellMind™ (calming, focus) and BodyAnew™ Cleanse. All will be available in the same dosage forms and sizes as currently sold.

The OTC Heel products Traumeel* and Zeel* will be phased out and replaced with T-Relief™ and T-Relief Arthritis™ from MediNatura. These products will be available in the same dosage forms and sizes as were Traumeel and Zeel, and will feature all-natural active ingredients. The BHI line of products will remain unchanged.

"MediNatura is dedicated to manufacturing and distributing high quality, FDA-regulated products, just as we did as Heel Inc.," said Scott Mitchell, MediNatura's vice president of operations and director of operations for Heel Inc.

Heel's OTC products currently sold exclusively to medical practitioners will be replaced by MediNatura's OTC product line, most of which will be priced 40 percent lower than current products. OTC Heel brands with international trademarks will be discontinued, including: Traumeel, Neurexan, Zeel, Oculoheel, Luffeel, Sinusin, Vinceel, Nectadyn, Adrisin, Gripp Heel, Viburcol, Vertigoheel, Spascupreel, Engystol and Lymphomyosot.*

"We know people can improve their lives by making healthy lifestyle choices, healthy food choices and healthy medicine choices," said Cliff Clive, CEO of Heel Inc., and founder and CEO of MediNatura. "MediNatura's mission is to improve lives with medicines from nature."

Customers can contact 1.844.621.7644 with questions.

*Trademarks of Heel GmbH

About MediNatura™ Inc.

MediNatura™ Inc., a Delaware Corporation headquartered in greater Philadelphia, is a homeopathic pharmaceutical company that makes medicines from nature.

Contact Us

Phone:
844-633-4628

Email Inquiries:
info@medinatura.com

Mailing Address:
MediNatura
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312